[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma]

Area of Science:

• Uro-oncology
• Medical Oncology
• Translational Research

Background:

• Systemic therapy historically showed limited success in uro-oncology, primarily in metastatic testicular tumors.
• Recent advancements are shifting treatment paradigms in uro-oncology.
• A deeper understanding of tumor biology is crucial for progress.

Purpose of the Study:

• To summarize practice-relevant innovations in systemic therapy for major uro-oncological diseases.
• To provide an overview of guideline updates for prostate cancer, urothelial carcinoma, and renal cell carcinoma.
• To highlight the impact of new developments on targeted treatment strategies.

Main Methods:

• Review of current guidelines for prostate cancer, transitional cell carcinoma of the bladder, and renal cell carcinoma.
• Analysis of recent advancements in systemic therapy for uro-oncological malignancies.
• Synthesis of practice-relevant innovations based on improved understanding of tumor biology.

Main Results:

• Systemic therapies are showing improved efficacy in metastatic testicular tumors.
• Targeted treatment strategies are emerging for metastatic prostate, urothelial, and renal cell carcinomas.
• Guideline-relevant innovations are transforming systemic therapy approaches.

Conclusions:

• Systemic therapy in uro-oncology is rapidly advancing.
• Improved understanding of tumor biology is driving the development of targeted therapies.
• These innovations offer improved treatment outcomes for patients with advanced uro-oncological cancers.